Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of CKD-331 in Healthy Volunteers
NCT05335044Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- May 2022
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CKD-331 in hypertension (HTN) and dyslipidemia (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Maximum Plasma Concentration of CKD-331 at 34 hours and Area Under the Concentration-time Curve to the Last Measurable Concentration at 34 hours. Started May 2022; status: completed.
02
Drugs
CKD-331
03
Conditions
hypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on NCT05335044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05335044.